Gibson, Dunn & Crutcher advised KKR on the acquisition of Vivitide Inc. by the global investor’s new life sciences portfolio company Biosynth Carbosynth.
Vivitide is a Gardner, Massachusetts-based maker of custom peptides and antibodies for the biotech industry.
McDermott Will & Emery said it represented Ampersand Capital Partners, Vivitide’s previous owner, which will roll over its entire stake and retain a “substantial” minority stake in the combined company.
Together, KKR and Ampersand plan to accelerate the combined company’s geographic expansion, broaden its capabilities, and expand its product portfolio, according to a statement.
“This acquisition marks an important milestone in our ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.